Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
MacroGenics (DE:M55)
BERLIN:M55
MacroGenics (M55) Stock Price & Analysis
4 Followers
M55 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€4.06 - €19.80
Previous Close€14.32
Volume0.00
Average Volume (3M)283.00
Market Cap
€886.80M
Enterprise Value€824.29M
Total Cash (Recent Filing)$100.96M
Total Debt (Recent Filing)$33.97M
Price to Earnings (P/E)N/A
Beta0.61
Next Earnings
May 09, 2024EPS Estimate
-€0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding62,432,013
10 Day Avg. Volume0
30 Day Avg. Volume283
Standard Deviation0.19
R-Squared0.09
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)6.23
Price to Sales (P/S)19.87
Price to Cash Flow (P/CF)-8.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue15.96
Enterprise Value/Gross Profit14.18
Enterprise Value/Ebitda-5.66
Forecast
1Y Price Target
€22.12Price Target Upside56.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
MacroGenics News
Bulls Say, Bears Say
Bulls Say
Clinical Trial OutcomesThe most advanced candidate, vobra duo (VD), shows a favorable safety profile with higher dose prioritization across multiple solid tumor types, based on recent data from the ongoing Phase II TAMARACK study.
Drug Development ProgressMGNX's innovative oncology therapeutics pipeline leverages the advances in antibody protein engineering to pursue first-in-class and/or best-in-class medicines, particularly within solid tumors.
Strategic Market PositioningMGNX's B7-H3 targeting ADC franchise is well-positioned in the rapidly growing market for metastatic castration-resistant prostate cancer, aiming to offer an alternative to current AR and PSMA-targeted therapies.
Bears Say
Clinical Trial ResultsDecline in efficacy is expected with the reduced dose of vobra duo.
Market CompetitionNoted competition from ifinatamab deruxtecan and XmAb808 could challenge vobra duo's market position.
Research And DevelopmentThe TAMARACK trial safety data was not accepted for presentation at the upcoming Annual Meeting.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
2.86% Other Institutional Investors
97.14% Public Companies and
Individual Investors
M55 FAQ
What was MacroGenics’s price range in the past 12 months?
MacroGenics lowest stock price was €4.06 and its highest was €19.80 in the past 12 months.
What is MacroGenics’s market cap?
Currently, no data Available
When is MacroGenics’s upcoming earnings report date?
MacroGenics’s upcoming earnings report date is May 09, 2024 which is in 3 days.
How were MacroGenics’s earnings last quarter?
MacroGenics released its earnings results on Mar 07, 2024. The company reported -€0.691 earnings per share for the quarter, missing the consensus estimate of -€0.143 by -€0.548.
Is MacroGenics overvalued?
According to Wall Street analysts MacroGenics’s price is currently Undervalued.
Does MacroGenics pay dividends?
MacroGenics does not currently pay dividends.
What is MacroGenics’s EPS estimate?
MacroGenics’s EPS estimate is -€0.6.
How many shares outstanding does MacroGenics have?
Currently, no data Available
What happened to MacroGenics’s price movement after its last earnings report?
MacroGenics reported an EPS of -€0.691 in its last earnings report, missing expectations of -€0.143. Following the earnings report the stock price went down -10.769%.
Which hedge fund is a major shareholder of MacroGenics?
Among the largest hedge funds holding MacroGenics’s share is RA Capital Management. It holds MacroGenics’s shares valued at 39M.
---
MacroGenics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€22.12 (56.99% Upside)
€22.12 (56.99% Upside)
Blogger Sentiment
Bullish
DE:M55 Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
123.49%
12-Months-Change
Fundamentals
Return on Equity
-6.15%
Trailing 12-Months
Asset Growth
5.98%
Trailing 12-Months
Company Description
MacroGenics
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.
---
M55 Earnings Call
Q4 2024
0:00 / 0:00
---
M55 Stock 12 Months Forecast
Average Price Target
€22.12
▲(56.99% Upside)
Technical Analysis
Gilead Sciences
―
Incyte
―
Syndax Pharmaceuticals
―
Crispr Therapeutics AG
―
MacroGenics
―
Best Analysts Covering M55
1 Year
1 Year Success Rate
11/19 ratings generated profit
1 Year Average Return
+53.37%
reiterated a buy rating last month
Copying Silvan Tuerkcan's trades and holding each position for 1 Year would result in 57.89% of your transactions generating a profit, with an average return of +53.37% per trade.
---